CliffBio
small molecule

CLOBAZAM

CLOBAZAM

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameCLOBAZAM
Active ingredientCLOBAZAM
Strength20MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2018
Marketing statusDISCN

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.